Drug treatment of hypertension – the future is combination therapy

Br J Cardiol 2003;10(Suppl 3):S1-S17 Leave a comment
Click any image to enlarge
Sponsorship Statement: This is a sponsored supplement to The British Journal of Cardiology. Details of sponsorship can be found by downloading the PDF.

Hypertension has long been recognised as a major risk factor for cardiovascular disease, especially stroke. The recent World Health Organisation (WHO) report which examined the major risk factors for global disease identified hypertension as one of the most important causes of the disease burden of developed and developing nations. Importantly, hypertension is easy to detect and amenable to treatment, there- by providing an enormous opportunity to impact favourably on this aspect of global disease risk.

Moreover, the evidence base supporting the treatment of hypertension is more extensive than any other in medicine and the findings of many clinical studies have revealed a consistent message: lowering blood pressure (BP) reduces mortality, stroke, coronary heart disease and heart failure. In recognition of the importance of hypertension as a major issue in public health, the Chief Medical Officer for England recently identified hypertension as one of his five priority areas.

Heart failure - BJC Learning programme
For healthcare professionals only

Disclaimer: UK prescribing information current at the date of publication of this supplement can be found by downloading the PDF. Medinews Cardiology Limited advises healthcare professionals to consult up-to-date Prescribing Information and the full Summary of Product Characteristics available from the manufacturers before prescribing any product. Medinews Cardiology Limited cannot accept responsibility for any errors in prescribing which may occur.